Sign in or Join FriendFeed
FriendFeed is the easiest way to share online. Learn more »
Sally Church

Sally Church

Interested in Pharma, Biotech, Science and cancer... Find me at http://www.pharmastrategyblog.com also love food, wine, the NFL and cricket. Hi!
On adaptive mechanisms of crizotinib resistance in ALK-positive lung cancer - http://pharmastrategyblog.com/2012...
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR : Nature : Nature Publishing Group - http://www.nature.com/nature...
Colon cancer patients harbouring BRAF(V600E) oncogenic lesion have poor prognosis and show only a very limited response to vemurafenib, despite it being effective for melanoma. Why? - Sally Church
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR : Nature : Nature Publishing Group - http://www.nature.com/nature...
Colon cancer patients harbouring BRAF(V600E) oncogenic lesion have poor prognosis and show only a very limited response to vemurafenib, despite it being effective for melanoma. Why? - Sally Church
J&J unblind Zytiga phase 3 trial in pre-chemotherapy castrate-resistant prostate cancer - http://pharmastrategyblog.com/2012...
The importance of metabolism in cancer research - http://pharmastrategyblog.com/2012...
nab-Paclitaxel and its potential role in pancreatic cancer - http://pharmastrategyblog.com/2012...
Video Report from 2012 European Association of Urology Congress in Paris - http://pharmastrategyblog.com/2012...
The challenge of prostate cancer drug approval versus reimbursement - http://pharmastrategyblog.com/2012...
Will combining custirsen and MDV3100 reduce resistance in advanced prostate cancer? - http://pharmastrategyblog.com/2012...
Combined VEGF and MET inhibition in some cancers may be better than either alone - http://pharmastrategyblog.com/2012...
Cancer Clinical Trials: Companion Diagnostics or Gene Sequencing? - http://pharmastrategyblog.com/2012...
Raised platelets reduce survival in ovarian cancer - http://pharmastrategyblog.com/2012...
A new fusion gene target in a rare soft tissue sarcoma - http://pharmastrategyblog.com/2012...
The role of the Androgen Receptor in breast cancer - http://pharmastrategyblog.com/2012...
Is ARN-509 (Aragon) potentially better than MDV-3100 (Medivation) in advanced prostate cancer? - http://pharmastrategyblog.com/2012...
Update on Medivation’s MDV3100 in advanced prostate cancer - http://pharmastrategyblog.com/2012...
On KRAS, NF-kB activation and pancreatic cancer - http://pharmastrategyblog.com/2012...
FDA approves Roche hedgehog inhibitor vismodegib/Erivedge in basal cell carcinoma - http://pharmastrategyblog.com/2012...
A new opportunity for vemurafenib in BRAFV600E colon cancer - http://pharmastrategyblog.com/2012...
Unravelling early colorectal cancer: the links between ROS, DNA methylation and inflammatory responses - http://pharmastrategyblog.com/2012...
New research demonstrates the link between inflammation and early development of colon cancer - http://pharmastrategyblog.com/2012...
RNAi as a potential biomarker for early breast cancer - http://pharmastrategyblog.com/2012...
Gene mutation and resistance to chemotherapy in colorectal cancer - http://pharmastrategyblog.com/2012...
ASH 2011 Update #3 – Multiple Myeloma - http://pharmastrategyblog.com/2012...
AVEO announces front-line data in renal cell cancer for tivozanib - http://pharmastrategyblog.com/2012...
I+just+entered+to+win+a+personal+assistant+for+a+whole+year+%28worth+%2410%2C400%21%29+Enter+here%3A - http://http%3a%2f%2fbit.ly%2fu6zadr/
I+just+entered+to+win+a+personal+assistant+for+a+whole+year+%28worth+%2410%2C400%21%29+Enter+here%3A - http://http%3a%2f%2fbit.ly%2fu6zadr/
ASH 2011 Update #2 – Non Hodgkins Lymphoma - http://pharmastrategyblog.com/2011...
Other ways to read this feed:Feed readerFacebook